Use of Cidofovir for Recurrent Respiratory Papillomatosis

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Recurrent Respiratory Papillomatosis
Interventions
DRUG

Cidofovir

With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.

DRUG

Placebo

On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER